Your browser doesn't support javascript.
loading
Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA gray zone?
Rius Bilbao, Leire; Valladares Gomez, Carmen; Aguirre Larracoechea, Urko; Pereira Arias, Jose Gregorio; Arredondo Calvo, Pablo; Urdaneta Salegui, Luis Felipe; Escobal Tamayo, Victor; Sanz Jaka, Juan Pablo; Recio Ayesa, Adrian; Mar Medina, Javier; Mar Medina, Carmen.
Afiliación
  • Rius Bilbao L; Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Urology, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. Electronic address: leire.riusbilbao@osakidetza.eus.
  • Valladares Gomez C; Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Clinical Laboratory Medicine, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Aguirre Larracoechea U; Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Research Unit, Spain.
  • Pereira Arias JG; IMQ Zorrotzaurre Hospital, Department of Urology, Spain.
  • Arredondo Calvo P; Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Urology, Spain.
  • Urdaneta Salegui LF; IMQ Zorrotzaurre Hospital, Department of Urology, Spain.
  • Escobal Tamayo V; Osakidetza Basque Health Service, Barakaldo-Sestao Integrated Health Organisation, Department of Urology, Spain.
  • Sanz Jaka JP; Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Department of Urology, Spain.
  • Recio Ayesa A; Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Department of Urology, Spain.
  • Mar Medina J; Osakidetza Basque Health Service, Debagoiena Integrated Health Organisation, Research Unit, Spain; Biodonostia Health Research Institute, Donostia-San Sebastián, Spain; Kronikgune Institute for Health Services Research, Barakaldo, Spain.
  • Mar Medina C; Osakidetza Basque Health Service, Barrualde-Galdakao Integrated Health Organisation, Department of Clinical Laboratory Medicine, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Clin Chim Acta ; 542: 117270, 2023 Mar 01.
Article en En | MEDLINE | ID: mdl-36893880
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article